Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec:68:104397.
doi: 10.1016/j.msard.2022.104397. Epub 2022 Nov 4.

Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis

Clàudia Coll-Martinez  1 , Ester Quintana  2 , Maria Buxó  3 , Judit Salavedra-Pont  4 , Laia Gasull-Vicens  5 , Ana Quiroga-Varela  6 , Lucienne Costa-Frossard  7 , Luisa María Villar  8 , Eva Fernández-Díaz  9 , Julia Gracia  9 , Yolanda Aladro  10 , Alejandro Méndez-Burgos  11 , Marta Cerezo  12 , Lluís Ramió-Torrentà  13 , Jordi Gich  14
Affiliations

Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis

Clàudia Coll-Martinez et al. Mult Scler Relat Disord. 2022 Dec.

Abstract

Background: The presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid is associated with a more severe clinical multiple sclerosis (MS) course.

Objective: To investigate LS-OCMB as a prognostic biomarker of cognitive long-term outcomes in MS.

Methods: Ninety-nine patients underwent neuropsychological assessment. Cognitive performance between LS-OCMB- and LS-OCMB+ patients was compared adjusting by age, education, anxiety-depression, disease duration, and disability.

Results: LS-OCMB+ patients of ∼13 years of disease duration performed worse on Symbol Digit Modalities Test (SDMT) (p = 0.005).

Conclusion: LS-OCMB+ perform worse on information processing speed and working memory (SDMT), suggesting that LS-OCMB could be a useful biomarker for long-term cognitive outcomes.

Keywords: Biomarker; Cognition; Cognitive impairment; Lipid-specific oligoclonal IgM bands; Multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/ or publication of this article: C.C.M: has received support for attending congresses from sanofi, merk, teva and novartis. E.Q: has nothing to disclose. M.B: has nothing to disclose. J.S.P: has nothing to disclose. L.G: has nothing to disclose. A.Q.V: has nothing to disclose. L.C.F: has received compensation for consulting services and speaking fees from Biogen, Novartis, Bayer, Merck, Sanofi, Janssen, Roche, Bristol Myers Squibb, TEVA and Almirall. LM.V: Received com compensation for consulting services and speaking fees from Biogen, Novartis, Merck, Sanofi, Genzyme, Roche, and Bristol Myers Squibb, Almirall. E.F.D: has received compensation for consulting services and/or speaking fees from Almirall, Biogen, Merck, Roche and Sanofi-Genzyme. J.G: has received compensation for consulting services and speaking fees from Biogen, Novartis, Merck, Sanofi, Genzyme, Roche and TEVA. Y.A: has received funding for research projects or in the form of conference fees, mentoring, and assistance for conference attendance from: Bayer, Biogen, Roche, Merck, Novartis, Allmirall and Sanofi-Genzime and Bristol Myers Squibb. A.M.B: has nothing to disclose. M.C: has nothing to disclose. L.R.T: has received compensation for consulting services and speaking fees from Biogen, Novartis, Bayer, Merck, Sanofi, Genzyme, Roche, Bristol Myers Squibb, TEVA and Almirall. J.G.F: has received speaking fees from Novartis, Teva, Sanofi and Merck.

LinkOut - more resources